Monoclonal antibodies (or mAb) have been authorized by the FDA to treat patients with mild to moderate COVID-19. The treatments are done by intravenous (IV) infusion in an outpatient setting and require a referral from the patients’ physician or clinic.
These antibodies are produced in a laboratory to mimic the human immune system response to infection. These man-made drugs block the COVID-19 virus from attaching to and entering human cells, thus neutralizing the virus that causes COVID-19.
Click here to go to the Louisiana Department of Health website for full details and resources